SCI Pharmtech Management
Management criteria checks 1/4
SCI Pharmtech's CEO is Wen-Chih Chou, appointed in Jun 2022, has a tenure of 2.5 years. directly owns 0.17% of the company’s shares, worth NT$18.48M. The average tenure of the management team and the board of directors is 2 years and 11.5 years respectively.
Key information
Wen-Chih Chou
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.5yrs |
| CEO ownership | 0.2% |
| Management average tenure | 2yrs |
| Board average tenure | 11.5yrs |
Recent management updates
Recent updates
Shareholders Shouldn’t Be Too Comfortable With SCI Pharmtech's (TWSE:4119) Strong Earnings
Nov 17
We Think That There Are More Issues For SCI Pharmtech (TWSE:4119) Than Just Sluggish Earnings
Mar 27Analysts Just Shipped A Captivating Upgrade To Their SCI Pharmtech, Inc. (TPE:4119) Estimates
Apr 07There May Be Reason For Hope In SCI Pharmtech's (TPE:4119) Disappointing Earnings
Mar 30SCI Pharmtech, Inc. (TPE:4119) Is Yielding 6.3% - But Is It A Buy?
Mar 08SCI Pharmtech (TPE:4119) Shareholders Booked A 54% Gain In The Last Three Years
Jan 25
Some SCI Pharmtech, Inc. (TPE:4119) Analysts Just Made A Major Cut To Next Year's Estimates
Dec 30Declining Stock and Solid Fundamentals: Is The Market Wrong About SCI Pharmtech, Inc. (TPE:4119)?
Dec 29Would SCI Pharmtech, Inc. (TPE:4119) Be Valuable To Income Investors?
Dec 08A Look At The Intrinsic Value Of SCI Pharmtech, Inc. (TPE:4119)
Nov 17CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | NT$484m |
| Jun 30 2024 | n/a | n/a | NT$138m |
| Mar 31 2024 | n/a | n/a | NT$276m |
| Dec 31 2023 | n/a | n/a | NT$295m |
| Sep 30 2023 | n/a | n/a | NT$377m |
| Jun 30 2023 | n/a | n/a | NT$390m |
| Mar 31 2023 | n/a | n/a | NT$331m |
| Dec 31 2022 | NT$6m | NT$4m | NT$309m |
| Sep 30 2022 | n/a | n/a | NT$210m |
| Jun 30 2022 | n/a | n/a | NT$192m |
| Mar 31 2022 | n/a | n/a | NT$55m |
| Dec 31 2021 | NT$3m | NT$2m | NT$56m |
Compensation vs Market: Insufficient data to establish whether Wen-Chih's total compensation is reasonable compared to companies of similar size in the TW market.
Compensation vs Earnings: Wen-Chih's compensation has increased by more than 20% in the past year.
CEO
Wen-Chih Chou
2.5yrs
Tenure
NT$5,623,386
Compensation
Mr. Wen-Chih Chou serves as Director & GM at SCI Pharmtech, Inc. since December 17, 2001 and also serves as it's President from July 2022 and was its Plant Manager since September 01, 2009 until July 2022....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.5yrs | NT$5.62m | 0.17% NT$ 18.5m | |
| Vice President of F&A Div. | 21.9yrs | no data | no data | |
| Assistant Vice President of Operating Div. | 1.4yrs | no data | no data | |
| Vice President of Technical Div. | 1.4yrs | no data | no data | |
| Sustainable Environment Team Manager & PDM/EH Manager | no data | no data | no data |
2.0yrs
Average Tenure
Experienced Management: 4119's management team is not considered experienced ( 2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 23yrs | NT$5.62m | 0.17% NT$ 18.5m | |
| Director | 23yrs | NT$330.00k | no data | |
| Independent Director | 9.5yrs | NT$810.00k | no data | |
| Chairman | 23yrs | NT$7.50m | 0.62% NT$ 66.4m | |
| Independent Director | 11.5yrs | NT$760.00k | no data | |
| Representative Director | less than a year | no data | 0% NT$ 0 | |
| Independent Director | 2.5yrs | NT$580.00k | 0.045% NT$ 4.9m |
11.5yrs
Average Tenure
62yo
Average Age
Experienced Board: 4119's board of directors are seasoned and experienced ( 11.5 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:00 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
SCI Pharmtech, Inc. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yenya Kuo | Capital Securities Corporation |
| Regina Lee | IBTS Investment Consulting Co., Ltd. |
| Zhennan Lee | Jih Sun Securities Investment Consulting Co., Ltd. |